Doliver Advisors LP Has $1.58 Million Holdings in Abbott Laboratories (NYSE:ABT)

Doliver Advisors LP grew its holdings in Abbott Laboratories (NYSE:ABT) by 3.2% in the 4th quarter, Holdings Channel reports. The fund owned 13,968 shares of the healthcare product maker’s stock after purchasing an additional 437 shares during the quarter. Doliver Advisors LP’s holdings in Abbott Laboratories were worth $1,580,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Groupama Asset Managment lifted its stake in Abbott Laboratories by 22.2% in the third quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 41,557 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new position in shares of Abbott Laboratories during the third quarter worth about $31,000. Itau Unibanco Holding S.A. acquired a new stake in Abbott Laboratories in the 2nd quarter valued at approximately $32,000. Peterson Financial Group Inc. acquired a new position in Abbott Laboratories during the 3rd quarter worth approximately $32,000. Finally, Valued Wealth Advisors LLC grew its stake in shares of Abbott Laboratories by 78.4% during the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock worth $33,000 after acquiring an additional 127 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on ABT shares. UBS Group increased their target price on shares of Abbott Laboratories from $143.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Royal Bank of Canada lifted their target price on Abbott Laboratories from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Evercore ISI raised their price target on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday. Barclays increased their price objective on Abbott Laboratories from $143.00 to $149.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Sanford C. Bernstein upped their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $131.57.

Abbott Laboratories Stock Performance

NYSE ABT traded down $0.31 during trading on Monday, reaching $113.52. The company’s stock had a trading volume of 2,330,714 shares, compared to its average volume of 3,402,624. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $121.64. The firm has a 50 day moving average price of $115.47 and a 200 day moving average price of $112.27. The firm has a market capitalization of $196.90 billion, a price-to-earnings ratio of 34.50, a price-to-earnings-growth ratio of 2.69 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.01. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.14 earnings per share. As a group, equities analysts anticipate that Abbott Laboratories will post 4.67 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 2.08%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio is presently 71.73%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.